•Eiamcharoen P, Gelli A, Byrne B, Keel MK (2022) Characterization of Pseudogymnoascus destructans conidial adherence to extracellular matrix: Association with fungal secreted proteases and identification of extracellular matrix binding proteins. Microbial Pathogenesis (in press)
•Gelli A, Nobile JC, Pericolini E, Wellington MA (2022) Editorial: Women in Fungal Pathogenesis 2021. Frontiers in Cellular and Infection Microbiology (in press)
•Bansal S*, Vu K,* Ruiwu Liu, Ajena Y, Xiao W, Menon S, Bennett A, Gelli A, Lam KS. (2022) Discovery of a potent antifungal peptide through OBOC combinatorial library screening.*Equal contribution. In press: ACS Infectious Disease, J of American Chemistry Society
•Garcia JA, Vu K, Thompson GR, Gelli A. (2022) Characterization of the growth and morphology of a BSL-2 Coccidioides posadasii strain that persists in the parasitic lifecycle at ambient CO2. bioRxiv 486294, J of Fungi, In press.
• Vu K, Blumwald E, & Gelli A. 2021. The antifungal activity of HMA, an amiloride analog and inhibitor of Na/H exchangers. Frontiers in Microbiology
• Aaron PA, Vu K, & Gelli A. 2020. An anti-virulence approach for preventing Cryptococcus neoformans from crossing the blood-brain barrier via novel natural product inhibitors of a fungal metalloprotease. mBio 11:e01249-20, Journal of the American Society of Microbiology.
•Aaron PA, & Gelli A. 2019. Harnessing the activity of the fungal metalloprotease, Mpr1, to promote crossing of nanocarriers through blood-brain barrier. ACS – Infectious Diseases, Journal of the American Chemistry Society.
•Vu K, Garcia JA, Gelli A. 2019. Cryptococcal meningitis and anti-virulence therapeutic strategies. Research Topic: The blood-brain barrier in infectious disease: Pathogenic mechanisms and therapeutic strategies. Frontiers in Cellular and Infection Microbiology
•Thompson GR III, Krois CR, Affolter VK, Everett AD, Varjonen EK, Sharon V, Singapuri A, Dennis M, McHardy I, Sik H, Fedor DM, Wiederhold NP, Aaron PA, Gelli A, Napoli JL, White SD. 2019. Fluconazole-induced alopecia: Examination in an animal model and human cohort. ASM Antimicrobial Agents & Chemotherapy, DOI: 10.1128/AAC.01384-18
•Gelli A. 2018. Editorial: A unique cytoskeleton-associated protein in Cryptococcus neoformans.
Virulence J, DOI:10.1080/21505594.2018.1451185;
•Aaron, PA, Jamklang M, Uhrig, JP, Gelli A. 2018. The blood-brain barrier internalizes Cryptococcus neoformans via the EphA2-tyrosine kinase receptor. Cellular Microbiology
•Vu K, Thompson GR III, Roe CC, Sykes JE, Edreibe EM, Lockhart SR, Meyer W, Engelthaler DM, Gelli A. 2018. Flucytosine resistance in two Cryptococcus gattii clinical isolates is indirectly mediated by the FCY2-FCY1-FUR1 pathway. Medical Mycology
•Na Pombjra S, M Salemi, Phinney BS, Gelli A. 2017. The metalloprotease, Mpr1, engages AnnexinA2 to promote the transcytosis of fungal cells across the blood-brain barrier. Front. Cell. Infect. Microbiol.30 June 2017 |
•Gelli A. 2016. Exploiting fungal mechanisms to breach the blood-brain barrier. Research Features Magazine – Neuroscience, issue: 103:24-27.
•Yang ML, Uhrig JP, Vu K, Singapuri A, Dennis M, Gelli A, & Thompson GR III. 2016. Fluconazole susceptibility in Cryptococcus gattii is dependent on the ATP binding cassette (ABC) transporter PDR11. Antimicrobial Agents & Chemotherapy 60(3):1202-7
•Sykes J, Hodge G, Singapuri A, Yang ML, Gelli A, & Thompson GR III. 2016. In vivo development of fluconazole resistance in Cryptococcus gattii isolates from a cat. Medical Mycology 55, 396-4
•Gelli A. Fungal metalloproteases and uses thereof. United States Patent, Patent No., 9,493,760 B2, Date of Patent: Nov. 15th, 2016.
•Vu K, Bautos JM and Gelli A. 2015. The Cch1-Mid1 high-affinity calcium channel contributes to the virulence of Cryptococcus neoformans by mitigating oxidative stress. Eukaryotic Cell 14(11):1135
•*Vu K, Tham R, Thompson GM, Bautos JM, Uhrig JP, and Gelli A. 2014. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. MBio 5(3):e1101-14. *Featured as Editor’s Pick. *Selected for Faculty1000Prime http://f1000.com/prime/718433707
•*Vu K, Eigenheer RA, Phinney BS and Gelli A. 2013. Cryptococcus neoformans promotes its transmigration into the CNS by inducing molecular and cellular changes in brain endothelial cells. Infection & Immunity 81:3139-47. *Featured in Spotlight: Chosen as article of significant interest by Editors (81:3059)
•Hong MP, Vu K, Bautos JM, Tham R, Jamklang M, Uhrig JP, and Gelli A. 2013. Activity of the fungal calcium channel pore CCH1, is dependent on a modulatory region of the subunit MID1. Eukaryotic Cell 12:142-50.
•Hong MP, Vu K, Bautos JM, and Gelli A. 2010. CCH1 restores intracellular calcium in fungal cells during ER stress. J. Biological Chemistry 285:10951-58.
•Vu K and Gelli A. 2010. The fungicidal activity of fluconazole with astemizole and its analogues against Cryptococcus neformans var., grubii and Cryptococcus gattii. Medical Mycology I-8.
•Vu K, Weksler B, Robero I, Couraud PO, and Gelli A. 2009. An immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of CNS infection by Cryptococcus neoformans. Eukaryotic Cell 8:1803-07.
•Vu K, Bautos JM, Hong MP, Gelli A. 2009. The functional expression of toxic genes: Lessons learned from molecular cloning of CCH1, a high-affinity calcium channel. Analytical Biochemistry 393:234.
•Liu M, and Gelli A. 2008. Elongation factor 3, EF3, associates with the calcium channel Cch1, and targets Cch1 to the plasma membrane of C. neoformans. Eukaryotic Cell 7:1118.
•Eigenheer RA, Lee YJ, Blumwald E, Phinney BS, Gelli A. 2007. Extracellular GPI-anchored mannoproteins and proteases of Cryptococcus neoformans. FEMS Yeast Research 7:499.